Status:
UNKNOWN
Role of Atosiban in Recurrent Implantation Failure
Lead Sponsor:
Al Baraka Fertility Hospital
Conditions:
Recurrent Implantation Failure
Eligibility:
FEMALE
22-40 years
Brief Summary
ET is the final stage of IVF which independently influences the treatment outcome. Successful embryo implantation is dependent on uterine receptivity. Atosiban is a novel class of drug which is effect...
Detailed Description
ET is a critical step of an IVF cycle that merits the utmost attention. Its success depends on the frequency of uterine contractions, the endometrial receptivity and the quality of embryos transferred...
Eligibility Criteria
Inclusion
- Women 22-40 years age
- Body mass index- 18.5-30 kg/m 2
- The normal uterine cavity on ultrasound scan
- At least one good quality embryo present for transfer
- Endometrium thickness ≥7.5 mm with endometrial volume 2-2.5 ml and good endometrial and subendometrial vascularity.
Exclusion
- 1\. Women ≥ 40 years age 2. Uterine abnormalities that can compromise the IRs (e.g., endometrial polyp, fibroids, hydrosalpinx, and adenomyosis) 3. Patients at risk of ovarian hyperstimulation syndrome 4. Patients with a history of hypersensitivity to atosiban 5. Endocrine dysfunction 6. Major organ dysfunction such as liver or kidney failure.
Key Trial Info
Start Date :
October 10 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 25 2021
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04118959
Start Date
October 10 2019
End Date
November 25 2021
Last Update
September 28 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Al-BARAKA FERTILITY HOSPITAL
Adliya, Manama, Bahrain, 15006